VANDA PHARMACEUTICALS INC. Business Acquisition, Pro Forma Revenue
VANDA PHARMACEUTICALS INC. (VNDA) reported Business Acquisition, Pro Forma Revenue of $79.33 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-13.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2015-03-13
- VANDA PHARMACEUTICALS INC. business acquisition, pro forma revenue for fiscal 2014 was $79.33M, a 5.40% increase from fiscal 2013.
- VANDA PHARMACEUTICALS INC. business acquisition, pro forma revenue for fiscal 2013 was $75.27M.
| Period end | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|
| 2014-12-31 | $79.33M 10-K · filed 2015-03-13 |
| 2013-12-31 | $75.27M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |